CHMP adopts positive opinion for BAVENCIO plus Axitinib for advanced renal cell carcinoma
The opinion was based on positive findings from the Phase III JAVELIN Renal 101 study, which demonstrated a significant extension in median progression-free survival (PFS) and a clinically